AstraZeneca plans to reveal new clinical data on various hematological conditions during the 65th Annual Meeting of the American Society of Hematology (ASH), scheduled for December 9-12, 2023.
The presentation will address 14 medications, including those related to rare diseases from its subsidiary Alexion.
Anas Younes, Senior VP of R&D in hematology, highlighted innovation in modalities such as antibody-drug conjugates, advanced immunotherapies and cell activators
T. Gianluca Pirozzi, Senior VP of R&D in hematology, focused on Alexion's contribution to the treatment of paroxysmal nocturnal hemoglobinuria.
AstraZeneca underscored its leadership in rare diseases by sharing data from its robust hematology pipeline, demonstrating its commitment to innovation. Calquence, a featured medication, will be discussed in relation to a Phase II trial that supports its safety and efficacy in treatment-naive patients with mantle cell lymphoma.
Additionally, safety results from five prospective trials will be presented, including Phase III randomized controlled trials, focusing on rates of ventricular arrhythmias in patients with CLL.
Gianluca Pirozzi expressed the company's pride in advancing its leadership in rare diseases and its commitment to improving patient outcomes. Beyond the developments in hematology, the presentations will address advances in various scientific modalities and platforms, such as immuno-oncology, immunoactivators, antibody-drug conjugates (ADC) and epigenetics, as part of AstraZeneca's comprehensive strategy to address cancer from different perspectives.
With information from: ConSalud.
Receive all industry news in our weekly Newsletter Scientific Dialectics.